Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 14c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.51), $0.14 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.18 million versus the consensus estimate of $2.65 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes
• Abitibi Metals names new CFO, halts drilling on Quebec fire order
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance